Please login to the form below

Not currently logged in
Email:
Password:

Abbott to pay $1.67bn to J&J

A US federal jury has ruled that Abbott is to pay Johnson & Johnson $1.67bn for infringing a patent

A US federal jury has ruled that Abbott is to pay Johnson & Johnson (J&J)  $1.67bn for infringing a patent that was allegedly used to develop its arthritis drug Humira (adalimumab).

The Texan court determined that Abbott's actions were willful and sided with J&J, the world's biggest healthcare company. J&J is owed $1.17bn in lost profits and $504m in royalties. Abbott has said it will appeal the verdict.

Abbott spokesperson Scott Stoffel remarked: "We are confident in the merits of our case and that we will prevail on appeal."

Centocor claimed that Humira is made using technology developed by New York University (NYU) and exclusively licensed to the J&J unit. The NYU property related to antibodies against tumour necrosis factor (TNF), which is linked to inflammation. Humira works by blocking the action of the TNF protein.

Humira generated $4.5bn in global sales last year, around 15 per cent of Abbotts' total revenue. The company has projected global sales of 15 to 20 per cent this year.

Kim Taylor, President of J&J's Centocor Ortho Biotech unit, said: "We are particularly gratified that the jury recognised our valuable intellectual property, finding our patent both valid and infringed."

30th June 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics